Federal Supply Schedule 36F79720D0075

Vifor (International) AG, a Swiss-based pharmaceutical manufacturer, holds a Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) multiple award vehicle with the Department of Veterans Affairs, with an original award date of February 1, 2020, and an ultimate completion date of July 31, 2026. The contract carries a ceiling value of $700,000 and operates without set-aside provisions, reflecting Vifor's status as a large, international pharmaceutical provider. The Department of Veterans Affairs National Acquisition Center funds this contract through various Veterans Integrated Service Networks. Under this FSS contract, Vifor supplies three primary pharmaceutical products: KORSUVA (difelikefalin), used to treat pruritus; MIRCERA (methoxy polyethylene glycol-epoetin beta), an anemia treatment; and KRYSTEXXA, a gout medication. These products are delivered through multiple delivery orders and supporting Blanket Purchase Agreements to VA healthcare facilities across the United States and international locations, with places of performance including Dublin, Ohio; Chicago, Illinois; La Vergne, Tennessee; Redwood City, California; and Switzerland.

Complementing the Federal Supply Schedule contract, Vifor maintains two significant single-award Blanket Purchase Agreements with the VA National Acquisition Center. The KORSUVA BPA, valued at $150,000 with an ultimate completion date of June 24, 2026, facilitates streamlined procurement of this pruritus treatment across multiple Veterans Integrated Service Networks. The MIRCERA BPA, originally awarded April 30, 2020, carried a potential value of $23.8 million over a base year plus four one-year option periods to support anemia treatment for the veteran population, though this agreement was subsequently cancelled due to administrative changes. The delivery orders under the FSS contract range in value from $65 to $11,310.02 and are structured as firm-fixed-price arrangements, enabling VA healthcare facilities to efficiently acquire these critical pharmaceutical products to support comprehensive veterans' healthcare programs nationwide.